89BIO INC. - COMMON STOCK

89bio to Participate in Upcoming Investor Conferences

29 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

89bio Appoints Francis Sarena as Chief Operating Officer

07 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

05 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

05 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

22 May 2024 16:05:00 By Nasdaq GlobeNewswire

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

14 May 2024 08:00:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 May 2024 16:05:00 By Nasdaq GlobeNewswire

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

09 May 2024 16:05:00 By Nasdaq GlobeNewswire

89bio to Participate in the BofA Securities 2024 Health Care Conference

08 May 2024 16:05:00 By Nasdaq GlobeNewswire

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

02 May 2024 16:05:00 By Nasdaq GlobeNewswire

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

17 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

27 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

12 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

08 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

89bio to Participate in the Leerink Partners Global Biopharma Conference

05 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

29 Feb 2024 16:05:00 By Nasdaq GlobeNewswire